Lung Cancer

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Panelists discuss how treatment selection between lorlatinib and alectinib for ALK-positive non–small cell lung cancer (NSCLC) should consider both efficacy data favoring lorlatinib and patient-specific factors such as neuropsychiatric history or cardiovascular comorbidities that might favor alectinib.

Panelists discuss how a 48-year-old fitness instructor with ALK-rearranged stage IV lung cancer and bone metastases was successfully treated with alectinib, experiencing manageable adverse effects while returning to modified teaching activities.

The investigational BET inhibitor is being investigated combined with abemaciclib or cisplatin/etoposide in NUT carcinoma in 2 clinical trials.

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell lung cancer.

Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.

Oncologic therapies approved in June included indications in genitourinary, lung, hematologic, and head and neck cancers.

Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated with prior immunotherapy.

Zirconium-89–labeled BMS-986279 demonstrated tumor uptake in fuc-GM1–positive lesions in patients with ES-SCLC.

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer harboring ROS1 mutations.

Dato-DXd was granted accelerated approval for use in adults with EGFR-mutated NSCLC after EGFR-targeted therapy and platinum-based chemotherapy.

Read Stacey Hield, BSN, RN, OCN's recommendations for the best use of durvalumab in non–small cell lung cancer.

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment option.

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, leading to prolonged survival.

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.

COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC.

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer.

The VENTANA MET (SP44) RxDx Assay is now FDA approved to identify patients with NSCLC eligible for telisotuzumab vedotin.

First-line maintenance therapy with lurbinectedin plus atezolizumab has the potential to become a new standard of care in extensive-stage small cell lung cancer.

The agent is currently being evaluated as both monotherapy and in combination with atezolizumab in patients with extensive stage SCLC in an ongoing, global phase 1 trial.

The combo showed safety and efficacy in patients with c-MET protein overexpression who progressed on prior osimertinib.

Telisotuzumab vedotin-tllv has earned accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression.

Early-phase LUPER trial results suggest the lurbinectedin/pembrolizumab combination may benefit patients with relapsed small cell lung cancer.